Clearside Biomedical

Clearside Biomedical Capital Intensity

Delisted

The Capital Intensity Ratio of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 1,509.98 %. In the previous year, Capital Intensity Ratio was 413.54 % — a change of 265.13% (higher).

Capital Intensity

1,509.98 %

YoY

265.13%

Last updated:

Capital Intensity Ratio of Clearside Biomedical is 2024 1,509.98 % . Capital Intensity Ratio of Clearside Biomedical was 2023 413.54 % . It decreases by 265.13% higher compared to the previous year.

The Clearside Biomedical Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2017
11,568.57 USD
Jan 1, 2018
147,066.67 USD
Jan 1, 2019
1,234.10 USD
Jan 1, 2020
244.87 USD
Jan 1, 2021
145.03 USD
Jan 1, 2022
3,857.14 USD
Jan 1, 2023
413.54 USD
Jan 1, 2024
1,509.98 USD
The Clearside Biomedical Capital Intensity history
YEARCapital IntensityYoY
1,509.98 %+265.13%
413.54 %-89.28%
3,857.14 %+2,559.54%
145.03 %-40.77%
244.87 %-80.16%
1,234.10 %-99.16%
147,066.67 %+1,171.26%
11,568.57 %-29.07%
16,309.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Capital Intensity Ratio of Clearside Biomedical is 1,509.98 % in 2024.

Capital Intensity Ratio of Clearside Biomedical changed from 413.54 % to 1,509.98 %, representing a 265.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical